<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055300</url>
  </required_header>
  <id_info>
    <org_study_id>LY03005</org_study_id>
    <nct_id>NCT02055300</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics Study of LY03005</brief_title>
  <acronym>LY03005SAD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of escalating single
      oral doses of LY03005 in healthy subjects and to characterize the pharmacokinetics (PK) of
      escalating single oral doses of LY03005.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>11 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of: Cmax,</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>LY03005 - 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 Dose Strength 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY03005 - 40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 Dose Strength 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY03005- 80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 Dose Strength 80mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY03005 - 120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 Dose Strength 120mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY03005 - 160</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 Dose Strength 160 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY03005 - 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 Dose Strength 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY03005 - 120 - Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 120mg under Fed Conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pristiq</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pristiq - 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY03005</intervention_name>
    <arm_group_label>LY03005 - 20</arm_group_label>
    <arm_group_label>LY03005 - 40</arm_group_label>
    <arm_group_label>LY03005- 80</arm_group_label>
    <arm_group_label>LY03005 - 120</arm_group_label>
    <arm_group_label>LY03005 - 160</arm_group_label>
    <arm_group_label>LY03005 - 200</arm_group_label>
    <arm_group_label>LY03005 - 120 - Fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>LY03005 - 20</arm_group_label>
    <arm_group_label>LY03005 - 40</arm_group_label>
    <arm_group_label>LY03005- 80</arm_group_label>
    <arm_group_label>LY03005 - 120</arm_group_label>
    <arm_group_label>LY03005 - 160</arm_group_label>
    <arm_group_label>LY03005 - 200</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meal</intervention_name>
    <arm_group_label>LY03005 - 120 - Fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pristiq</intervention_name>
    <arm_group_label>Pristiq</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are capable of giving informed consent and complying with study procedures;

          2. Are between the ages of 18 and 45 years, inclusive;

          3. Female subjects have a negative pregnancy test result prior to enrollment, and meet
             the following criteria defined as:

               1. If child-bearing potential, agree to avoid pregnancy during the study and one
                  month after the end of the study by using at least one effective contraceptive
                  method(s), such as an intrauterine device (IUD), diaphragm with spermicide, oral
                  contraceptives used for at least one month prior to screening, injectable
                  progesterone, or progesterone sub-dermal implants.

               2. Surgically sterile for at least 3 months prior to screening by one of the
                  following means:

                    -  Bilateral tubal ligation

                    -  Salpingectomy (with or without oophorectomy)

                    -  Surgical hysterectomy

                    -  Bilateral oophorectomy (with or without hysterectomy)

               3. Postmenopausal, defined as one of the following:

                    -  Last menstrual period greater than 12 months prior to screening

          4. Considered healthy by the Principal Investigator, based on a detailed medical history,
             full physical examination, clinical laboratory tests, 12-lead ECG and vital signs;

          5. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6
             months before screening;

          6. Body mass index (BMI) of 19 to 32 kg/m2 inclusive and body weight not less than 50 kg;

          7. Willing and able to adhere to study restrictions and to be confined at the clinical
             research center.

        Exclusion Criteria:

          1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,
             immunologic, lipid metabolism disorders, or drug hypersensitivity;

          2. Subjects with a mean systolic blood pressure of three measurements &gt;130 mmHG, or a
             mean diastolic blood pressure of three measurements &gt;90 mmHG at screening.

          3. History or presence of malignancy other than adequately treated basal cell skin cancer

          4. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg), or hepatitis C antibody;

          5. A history of seizure. However, a history of febrile seizure is allowed;

          6. Positive pregnancy test result, or plan to be pregnant if female;

          7. A hospital admission or major surgery within 30 days prior to screening;

          8. Participation in any other investigational drug trial within 30 days from the last
             dosing of other trials to screening;

          9. A history of prescription drug abuse, or illicit drug use within 6 months prior to
             screening;

         10. A history of alcohol abuse according to medical history within 6 months prior to
             screening;

         11. A positive screen for alcohol, drugs of abuse;

         12. Tobacco use within 6 months prior to screening;

         13. An unwillingness or inability to comply with food and beverage restrictions during
             study participation;

         14. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or
             blood products) or acute loss of blood during the 90 days prior to screening;

         15. Use of prescription or over-the-counter (OTC) medications, and herbal (including St
             John's Wort, herbal teas, garlic extracts)within 14 days prior to dosing (Note: Use of
             acetaminophen at &lt; 3g/day is permitted until 24 hours prior to dosing);

         16. A history of intolerance or hypersensitivity to venlafaxine or desvenlafaxine or any
             excipients;

         17. Patients with a history of suicide attempt in the past 6 months and/or seen by the
             investigator as having a significant history of risk of suicide or homicide;

         18. An unwillingness of male participants to use appropriate contraceptive measures if
             engaging in sex intercourse with a female partner of childbearing potential.
             Appropriate measures include use of a condom and spermicide and, for female partners,
             use of an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives,
             injectable progesterone, progesterone sub-dermal implants, or a tubal ligation. Sexual
             intercourse with pregnant or lactating women is prohibited.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Li</last_name>
    <role>Study Chair</role>
    <affiliation>Luye Pharma Group Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medpace</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

